RxDoctor Payments Data

Ana Kumar, MD

Rheumatology · Edmond, OKNPI 1215905971

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $713 of the $1,001 with a category attached, or 71.3%. 9 manufacturers reported payments, led by Amgen at 37.6% of the total. That places this record below the midpoint for rheumatology clinicians in OK, where the typical reported total is $4,359.

$1,001in general payments, 2019–2025

Across 33 payments — averaging $30.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$376
  • AbbVie$237
  • Inogen, Inc.$160
  • Lilly USA, LLC$90
  • Novartis$35
  • GSK$31
  • plus $72 from 3 others

What the payments were for

  • Food & beverage$71371%
  • Education$28729%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen9$376
AbbVie3$237
Inogen, Inc.11$160
Lilly USA, LLC2$90
Novartis2$35
GSK2$31
AstraZeneca2$28
Lundbeck LLC1$23
Bioventus LLC1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,001 in reported general payments places this provider in the 25th percentile of 67 rheumatology providers in Oklahoma.

See all rheumatology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$4,779,951
Medicare patients
839
Services billed
287,370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept47$368,088
Humira(Cf) PenAdalimumab40$272,154
Xeljanz XrTofacitinib Citrate39$220,836
Humira(Cf)Adalimumab17$117,305
BenlystaBelimumab14$51,406
Teriparatide13$32,346
Hydroxychloroquine Sulfate707$22,957
SavellaMilnacipran Hcl16$11,643
LinzessLinaclotide18$11,481
OxycontinOxycodone Hcl31$11,088
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen381$10,860
Emgality SyringeGalcanezumab-Gnlm13$9,032
MethotrexateMethotrexate Sodium288$7,801
Pilocarpine Hcl59$5,928
Leflunomide84$5,244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira(Cf), Savella, Linzess$237$140,42851 claims
GSKBenlysta$31$51,40614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 67 rheumatology providers in Oklahoma.

Other rheumatology in Edmond

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →